semaglutide and type 2 diabetes The FDA requires manufacturers to assess the cardiovascular risk of all new therapies for diabetes. Semaglutide, a glucagon like peptide-1 analogue, lowers blood glucose, but does it increase Semaglutide-Mediated Remodeling of Adipose Tissue

A 2026 review in the New England Journal of Medicine noted that questions about long-term dosing and durability of results remain open areas of research, not settled strategy

Harm Reduction An approach to substance use that focuses on minimizing negative consequences rather than demanding complete abstinence

Common side effects for all three include gastrointestinal issues like nausea, vomiting, diarrhea, and constipation

How it works Step 1 Begin with a virtual consultation where an Elase provider will review your medical history and discuss your weight loss goals to determine if the treatment is right for you

Treatment resulted in 12 kg weight loss, reduced body/visceral fat, improved glycemic variability, lower GMI with stable TIR, and modest insulin dose reduction